Brokers Issue Forecasts for DVAX Q2 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Dynavax Technologies in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. White expects that the biopharmaceutical company will post earnings per share of $0.08 for the quarter. HC Wainwright currently has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.

Separately, StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Tuesday.

Dynavax Technologies Stock Performance

DVAX stock opened at $12.48 on Thursday. Dynavax Technologies has a 1 year low of $9.74 and a 1 year high of $14.41. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of 96.01 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock’s fifty day moving average is $12.77 and its two-hundred day moving average is $11.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the period. Sanctuary Advisors LLC lifted its holdings in Dynavax Technologies by 9.1% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 1,484 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares in the last quarter. US Bancorp DE lifted its stake in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in Dynavax Technologies by 1.2% during the third quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company’s stock worth $2,445,000 after buying an additional 2,629 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.